Guidelines For Sinovac Vaccine - 6303
Guidelines For Sinovac Vaccine - 6303
Guidelines For Sinovac Vaccine - 6303
1
Target Audience
• All the concerned national, provincial & district health authorities and health care workers who are
involved in the COVID-19 vaccine operations, establishment, and management of COVID-19
Vaccination Counters both at public and private health facilities.
Vaccine Dose
• Two doses should be administered by intramuscular injection in the deltoid region of the upper arm.
• The second dose should be given 6 weeks after the first dose.
• Each vial (syringe) contains 0.5 mL of single dose containing 600S8U of inactivated SARS-CoV-2
virus as antigen.
2
Who should NOT receive CoronaVac:
• Individuals who are below 18 years of age. The safety and efficacy of CoronaVac in children and
adolescents below 18 have yet to be established.
• People with history of allergic reaction to CoronaVac or other inactivated vaccine, or any
component of CoronaVac (active or inactive ingredients, or any material used in the process).
• Previous severe allergic reactions to the vaccine (e.g. acute anaphylaxis, angioedema, dyspnea, etc.).
• People with severe neurological conditions (e.g. transverse myelitis, Guillain-Barré syndrome,
demyelinating diseases, etc.).
Shelf life
Vaccine Storage
Pre-Vaccination Phase
• Designated Nurse/Skilled Immunization Staff/Vaccinator/ Doctor should administer the vaccine
• The CVC staff should have prior training on vaccine handling, cold chain, Infection Prevention
Protocols, Reporting Tools / MIS and Adverse Events Following Immunization
Vaccination Phase
Administration
• Precautions
o CoronaVac for intramuscular (IM) injection only, in the deltoid muscle.
o The vaccine should be inspected visually prior to administration and discarded if particulate matter
or differences in the described appearance are observed.
3
o Contraindications, warnings and precautions to injection must be checked prior to administering the
study injection.
o This vaccine is strictly prohibited by intravascular injection. There are no data yet on the safety and
efficacy of this vaccine by subcutaneous or intra-dermal injection.
o Before use, check whether the packaging container, label, appearance, and expiration date meet the
requirements. It should not be used under following circumstances: damage or crack, spots, stains,
scratches on the outer surface of the vaccine container, unclear label, expired vaccine, or abnormal
appearance.
o Adequate treatment provisions, including epinephrine injection and emergency treatment, should be
available for immediate use. Individuals should be observed for at least 30 minutes on site after
vaccination.
o Avoid exposing CoronaVac to the disinfectant during use.
o Do not freeze. It should be administered immediately after opening the vial.
o Avoid contact with vaccine fluid when opening.
o The vaccine does not contain any preservative
o To facilitate the traceability of the vaccine, the name and the batch number of the administered
product must be recorded for each recipient
Steps
o Wear mask and observe COVID-19 SOPs
o Greet the client
o Complete verification process in the National Immunization Management System (NIMS)
o Take consent. Since vaccine may be administered to both walk-in and previously registered patients,
consent should be worded accordingly, e.g “I agree to receive this COVID-19 vaccine because I
have registered myself in the system” or “ I agree to receive this COVID-19 vaccine to avail walk-
in vaccination facility”. (Annex)
o Expose site (deltoid of non-dominant arm) for administration
o Explain the procedure and inform that some pain on giving injection, discomfort at the site of
injection or fever after the injection, may happen
o Take vaccine vial out of the vaccine carrier
o Open the vial by removing plastic cover/cap
o Take out 22G-25G 0.5ml syringe and remove needle cap
o Discard the needle and syringe in safety box
o Insert the syringe needle through the top rubber pad of vaccine vial
o Draw 0.5ml of diluted vaccine from the vial
o Inject intra muscularly at the site of injection at an angle of 90⁰ (right angle) following “No-touch
technique”
During vaccination, do NOT
o Touch the rubber pad of vaccine vial (causes contamination and result in AEFI)
4
o Recap needle of syringes (can cause needle stick injuries)
5
Systemic adverse reactions
Very common: headache, fatigue
o Common: myalgia, nausea, diarrhea, arthralgia, cough, chills, pruritus, loss of appetite, rhinorrhea,
sore throat, nasal congestion, abdominal pain
o Uncommon: vomiting, hypersensitivity, fever, tremor, flushing, edema, dizziness, drowsiness
o Rare: muscle spasms, eyelid edema, nose bleeds/epistaxis, abdominal distension, constipation,
hyposmia, hot flashes, hiccup, conjunctival congestion
o
Severity of adverse reactions
o The severity of adverse reactions observed in these clinical trials is mainly Grade 1 (mild), the
incidence rate of adverse reactions for Grade 3 and the above was 1.31%.
o Grade 3 and above adverse reactions include pain at injection site, cough, fever, headache, sore
throat, abdominal pain, dizziness and drowsiness.
o
Serious adverse event (SAE)
o No serious adverse event related to vaccination was identified